Sanofi Zerinolflu Medical Device 20 Effervescent Tablets
- Brand: SANOFI Srl
- Product Code: 035191030
- Availability: In Stock
- Purchase 3 items for 9.73€ each
- Purchase 4 items for 9.53€ each
- Purchase 5 items for 9.33€ each
Medicinal which comes in the form of effervescent tablets, ideal for the treatment of flu and cold symptoms. Thanks to its active ingredients (paracetamol 300 mg, chlorfenamine maleate 2 mg, sodium ascorbate 280 mg corresponding to vitamin C 250 mg), Zerinolflu falls into the category of analgesics and antipyretics and proves to be an excellent ally to combat the annoying disorders related to colds and to the flu.
Adults: 1 effervescent tablet 2 times a day. Dissolve the effervescent tablet in about ½ glass of water.
An effervescent tablet contains: active ingredients: paracetamol 300 mg; chlorfenamine maleate 2 mg; 280 mg sodium ascorbate corresponding to vitamin C 250 mg. For the full list of excipients,
Excipients: citric acid anhydrous, sodium bicarbonate, sodium carbonate, sorbitol, polyvinylpyrrolidone, dimethicone, aspartame, orange flavor, lemon flavor.
Hypersensitivity to the active substances, to any of the excipients or other substances strictly related from the chemical point of view; in particular towards antihistamines of similar chemical structure to chlorophenamine. The product is contraindicated during pregnancy and lactation. Paracetamol-based products are contraindicated in patients with manifested glucose-6-phosphate dehydrogenase deficiency and in those with severe hemolytic anemia. Hepatocellular insufficiency. For its anticholinergic effects it should not be used in case of glaucoma, prostatic hypertrophy, bladder neck obstruction, pyloric and duodenal stenosis or other tracts of the gastrointestinal and urogenital apparatus.
Administer with caution in subjects with renal or hepatic impairment. During treatment with paracetamol before taking any other medication, check that it does not contain the same active ingredient, as if paracetamol is taken in high doses, serious adverse reactions may occur. Ask the patient to contact the doctor before attaching any other medication. See also the entry "Interactions". If the fever persists for more than three days or if the symptoms do not improve and others appear within three days or are accompanied by a high fever, rash, excessive mucus and persistent cough, consult your doctor in order to establish the new diagnosis. Do not administer for more than 3 consecutive days without consulting your doctor. The drug should be taken on a full stomach. Zerinolflu contains an antihistamine. At the common therapeutic doses, antihistamines have very variable secondary reactions from subject to subject and from drug to drug. The most frequent secondary effect is the sedation that can manifest itself with drowsiness, of this they must be warned those who can conduct motor vehicles or wait for operations that require integrity of the degree of vigilance. Particular attention should be paid to determining the dose in the elderly due to their greater sensitivity towards the drug. High or prolonged doses of the product may cause high-risk liver disease and serious kidney and blood changes. Ascorbic acid (vitamin C) should be used with caution by subjects who suffer, or have suffered in the past, nephrolithiasis (renal calculosis) and those suffering from G6PD (Glucose-6-phosphate-dehydrogenase), hemochromatosis, deficiency thalassemia or sideroblastic anemia. Zerinolflu effervescent tablets contain aspartame, source of phenylalanine; this must be taken into account by patients suffering from phenylketonuria (enzyme phenylalanine hydroxylase deficiency) due to the risk linked to the accumulation of the amino acid phenylalanine in these subjects.
It is contraindicated.
With the use of paracetamol skin reactions of various types and severities have been reported including cases of urticaria, erythema multiforme, Stevens-Johnson syndrome and epidermal necrolysis. Hypersensitivity reactions such as angioedema, laryngeal edema, anaphylactic shock have been reported. In addition, the following side effects have been reported: thrombocytopenia, leucopenia, anemia, agranulocytosis, abnormal liver function and hepatitis, kidney changes (acute renal failure, interstitial nephritis, haematuria, anuria), gastrointestinal reactions and vertigo. Zerinolflu can cause above all drowsiness, asthenia, photosensitization, dry mouth, urinary retention, increased viscosity of bronchial secretions. Reporting of suspected adverse reactions The reporting of suspected adverse reactions occurring after authorization of the medicinal product is important as it allows continuous monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it/it/responsabili.
In case of overdose, depressive effects on the central nervous system, drowsiness, lethargy, respiratory depression are generally observed. In case of overdosing, paracetamol, contained in Zerinolflu, can cause hepatic cytolysis that could evolve towards massive necrosis. N-acetylcysteine, administered in the hours immediately following ingestion of paracetamol is effective in limiting hepatic damage. It is advisable to resort to the usual measures to remove from the gastrointestinal tract the unabsorbed material by induction of vomit or possibly gastric lavage; the patient must be monitored by practicing supportive therapy.
Use with extreme caution and under strict control during chronic treatment with drugs that may induce liver monoxigenase induction or when exposed to substances that may have such effect (eg rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine) . The administration of paracetamol can interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycaemia (by the glucose-oxidase-peroxidase method). Like all antihistamine preparations, Zerinolflu can mask the first signs of ototoxicity of certain antibiotics. Zerinolflu can interact with alcohol, tricyclic antidepressants, neuroleptics or other drugs with depressive action on the central nervous system such as barbiturates, sedatives, tranquilizers, hypnotics and therefore should not be taken during therapy. To avoid significant interactions, Zerinolflu should not be taken concomitantly with anticoagulants, metoclopramide, other anticholinergic substances. The usual use of anticonvulsant drugs or oral contraceptives can, with an enzymatic induction mechanism, accelerate the metabolism of paracetamol. It is not advisable to use the product if the patient is being treated with anti-inflammatories. The product is also contraindicated in patients treated with monoamine oxidase inhibitors (IMAO) or in the two weeks following this treatment.
Do not store above 25 ° C.